A supervisor inspects pre-filled syringes of the biosimilar of Adalimumab at a production facility of the Zydus group. Biosimilars are generic equivalents of biologic drugs, a new class of medicines, and are more complex than chemical generics. (Image: AFP)
Generics and biosimilars warrant separate strategies and approaches. The Centre needs to ensure tighter controls before approval and periodic quality checks to ensure every batch shows consistent quality
Himani Chandna writes on healthcare and pharmaceuticals, policy, R&D and corporate updates, and has a ringside view of India’s battle against the ...Read More
